scholarly journals Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Wenjing Zhou ◽  
Thomas Sollie ◽  
Tibor Tot ◽  
Carl Blomqvist ◽  
Shahin Abdsaleh ◽  
...  
Keyword(s):  
Lower Risk ◽  
Carcinoma In Situ ◽  
Invasive Carcinoma ◽  
Population Based ◽  
Her2 Overexpression ◽  
Lymphocyte Infiltration ◽  
High Nuclear Grade ◽  
Worse Prognosis

Casting-type calcifications and a histopathological picture with cancer-filled duct-like structures have been presented as breast cancer with neoductgenesis. We correlated mammographic features and histopathological neoductgenesis with prognosis in a DCIS cohort with long follow-up. Mammographic features were classified into seven groups according to Tabár. Histopathological neoductgenesis was defined by concentration of ducts, lymphocyte infiltration, and periductal fibrosis. Endpoints were ipsilateral (IBE) in situ and invasive events. Casting-type calcifications and neoductgenesis were both related to high nuclear grade, ER- and PR-negativity, and HER2 overexpression but not to each other. Casting-type calcifications and neoductgenesis were both related to a nonsignificant lower risk of invasive IBE, HR 0.38 (0.13–1.08) and 0.82 (0.29–2.27), respectively, and the HR of an in situ IBE was 0.90 (0.41–1.95) and 1.60 (0.75–3.39), respectively. Casting-type calcifications could not be related to a worse prognosis in DCIS. We cannot explain why a more aggressive phenotype of DCIS did not correspond to a worse prognosis. Further studies on how the progression from in situ to invasive carcinoma is driven are needed.

Significance of HER2/neu overexpression in pure ductal carcinoma in situ: A clinicopathologic study with long-term follow-up.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 85-85
Author(s):  
Zeina Al-Mansour ◽  
Thomas Stockl ◽  
Ashraf Khan ◽  
Richard Horner ◽  
Ediz Cosar ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Disease Recurrence ◽  
Nuclear Grade ◽  
Her2 Overexpression ◽  
Her2 Positive ◽  
High Nuclear Grade

85 Background: The prognostic value of HER2 (c-ERB2) overexpression in invasive breast cancer is well known, and correlates with aggressivene behavior. HER2 overexpression was reported in 13-56% of ductal carcinoma in-situ (DCIS). The significance of HER2 overexpression in DCIS has yet to be elucidated. The aim of this study was to correlate HER2 status with known prognostic indicators of DCIS and to evaluate whether the HER2 overexpression correlates with disease recurrence. Methods: All cases of DCIS diagnosed at our institution between 2000 and 2005 were retrieved. Cases without follow-up, those treated with mastectomy or those with concurrent invasive component were excluded. Clinicopathologic data were collected, including age at time of diagnosis, size of the lesion, nuclear grade, presence of comedo necrosis, margin status, estrogen (ER) and progesterone receptor (PR) status, type of adjuvant treatment received and length of follow-up. A representative block from each case was immunostained using the Hercept test. Slides were reviewed by 2 pathologists and interpreted in accordance with ASCO/CAP guidelines. Equivocal cases were reflexed for FISH testing. Results: A total of 152 cases were examined. Mean follow-up period was 77 months (range 12 to 138 months). HER2 was overexpressed in 49 cases (33%), and was significantly associated with high nuclear grade and presence of comedo necrosis. HER2-positive patients were more likely to be ER and PR negative. HER2 positive and negative patients did not differ significantly with respect to age at presentation or size of DCIS. On univariate analysis, HER2-type DCIS showed a higher risk of recurrence (P=0.037), however, this trend did not reach statistical signifance on multivariate analysis. Conclusions: HER2 overexpression was found to be associated with high nuclear grade, comedo necrosis as well as negativity for ER and PR but not with age or the size of DCIS. Patients with HER2-type DCIS (ER/PR-, HER2+) had a higher risk of disease recurrence than other types. However, after adjusting for all the other clinical variables, the molecular phenotype did not withhold its statistical significance as an independent predictor for recurrence.

Laryngeal Dysplasia: Epidemiology and Treatment Outcome

1995 ◽  
Vol 104 (8) ◽  
pp. 596-602 ◽  
Author(s):  
Keith E. Blackwell ◽  
Thomas C. Calcaterra ◽  
Yao-Shi Fu
Keyword(s):  
Treatment Group ◽  
Carcinoma In Situ ◽  
Invasive Carcinoma ◽  
Endoscopic Therapy ◽  
Partial Laryngectomy ◽  
Severe Dysplasia ◽  
Long Term Follow Up

A retrospective analysis was undertaken of 65 patients with long-term follow-up for laryngeal squamous dysplasia. Based on the degree of dysplasia demonstrated on initial biopsy, 0 of 6 patients showing hyperkeratosis without dysplasia, 3 of 26 patients (12%) showing mild dysplasia, 5 of 15 patients (33%) showing moderate dysplasia, 4 of 9 patients (44%) showing severe dysplasia, and 1 of 9 patients (11%) showing carcinoma in situ eventually progressed to invasive carcinoma. An analysis was made of the impact of various treatment modalities in 33 patients demonstrating moderate dysplasia, severe dysplasia, or carcinoma in situ. Invasive carcinoma developed in 10 of 21 patients (48%) treated endoscopically and 0 of 12 patients treated by more aggressive therapy, including external beam radiotherapy, partial laryngectomy, or total laryngectomy. Of the patients in the endoscopic therapy group who developed invasive carcinoma, all were salvaged successfully. The overall rate of laryngeal preservation was 15 of 21 patients (71%) in the endoscopic treatment group and 11 of 12 patients (92%) in the aggressive treatment group. This difference is not statistically significant. We conclude that there is a moderately high rate of progression to invasive carcinoma in patients undergoing repeated endoscopic therapy for intraepithelial neoplasms of the larynx. However, with close, long-term follow-up, patients undergoing endoscopic therapy have an overall outcome similar to that in patients treated with partial laryngectomy or radiotherapy prior to developing invasive disease.

scholarly journals Mucocele-like Lesion of the Breast Diagnosed on Core Biopsy: Histologic and Clinical Analysis of 78 Cases With Focus on Features Associated With Upgrade

2021 ◽  
Author(s):  
William S. Towne ◽  
Aya Y. Michaels ◽  
Paula S. Ginter
Keyword(s):  
Core Biopsy ◽  
Carcinoma In Situ ◽  
Invasive Carcinoma ◽  
Ductal Carcinoma ◽  
Atypical Ductal Hyperplasia ◽  
Clinical Analysis ◽  
Atypical Lobular Hyperplasia ◽  
Ductal Hyperplasia

Context.— Mucocele-like lesion of the breast (MLL) is an uncommon entity, and recent studies show low rates of upgrade from core needle biopsy (CNB) to excision. Objective.— To evaluate features associated with upgrade of MLLs diagnosed on CNB. Design.— Seventy-eight MLLs diagnosed on CNB from 1998–2019 and subsequent excisions were reviewed. Histologic parameters evaluated included the presence of atypia, presence and morphology of calcifications, and morphologic variant (classic [C-MLL], duct ectasia–like [DEL-MLL], or cystic mastopathy–like [CML-MLL]). Results.— Overall, 45 MLLs lacked atypia and 33 were associated with atypia (atypical ductal hyperplasia, 32; atypical lobular hyperplasia, 1). Most were C-MLLs (61) with fewer DEL-MLLs (14) and CML-MLLs (3). Half showed both coarse and fine calcifications, with fewer showing only coarse or fine calcifications, and some showing none. Subsequent excision or clinical follow-up was available for 25 MLLs without atypia—of which 2 (8.0%) were upgraded to ductal carcinoma in situ (DCIS)—and 23 with atypia, of which 4 (17.4%) were upgraded to DCIS. No cases were upgraded to invasive carcinoma. All upgraded cases showed coarse calcifications on CNB, and all upgraded cases were associated with residual calcifications on post-CNB imaging. Conclusions.— Most MLLs present as calcifications and nearly half are associated with atypia. Upgrade to DCIS is twice as frequent in MLLs with atypia versus those without. A predominance of coarse calcifications and the presence of residual targeted calcifications following core biopsy may be associated with higher upgrade rates.

scholarly journals Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tae-Kyung Yoo ◽  
Sang Hyun Park ◽  
Kyung Do Han ◽  
Byung Joo Chae
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Lower Risk ◽  
Carcinoma In Situ ◽  
Cardiovascular Events ◽  
Ductal Carcinoma ◽  
Population Based ◽  
Control Group ◽  
Invasive Group ◽  
Screening Programs

Abstract Background Ductal carcinoma in situ (DCIS) patients are usually diagnosed through cancer screening programs, suggesting a healthy user effect. In this population-based cohort, we assessed the risk of cardiovascular events and mortality in DCIS patients. Methods Using the Korean National Health Insurance Service database, 13,740 women, who were initially diagnosed with DCIS between 2007 and 2013, were analyzed. A control group was matched according to age and the year of diagnosis at a 3:1 ratio (n = 41,220). Follow-up was performed until 2016. Subgroup analysis was performed according to the subsequent diagnosis of invasive breast cancer within 1 year: pure DCIS and DCIS+Invasive group. Results DCIS patients were more likely to have underlying diseases, higher incomes, and to live in urban districts compared to the control group. Women diagnosed of DCIS had lower myocardial infarct risk (hazard ratio [HR] 0.64; 95% confidence interval [CI] 0.46–0.90) and lower stroke risk (HR 0.77; 95% CI 0.60–0.98) compared to the control group. This trend of lower risk was sustained after adjusting for age, income, residence and comorbidities. The mortality rate was similar between the control group and pure DCIS patients but was higher in the DCIS+Invasive group (HR 1.63; 95% CI 1.34–1.98). However, after adjusting for age, income, residence and comorbidities, mortality did not differ between the control group and DCIS+Invasive group (HR 0.99; 95% CI 0.78–1.24). Conclusions DCIS patients were at lower risk for MI and stroke compared to a control group despite a higher rate of comorbidities, which may reflect changes in health behaviour. The importance of managing pre-existing comorbidities along with DCIS treatment should be emphasized.

Squamous cell hyperplasia of the larynx

1987 ◽  
Vol 101 (6) ◽  
pp. 579-588 ◽  
Author(s):  
P. Olde Kalter ◽  
H. Lubsen ◽  
J. F. M. Delemarre ◽  
G. B. Snow
Keyword(s):  
Squamous Cell ◽  
Carcinoma In Situ ◽  
Invasive Carcinoma ◽  
Response To Treatment ◽  
Class Iii ◽  
Cell Hyperplasia ◽  
The Mean ◽  
Almost All

AbstractAccording to Kleinsasser's classification 200 patients with squamous cell hyperplasia, seen between 1963–1981, were reviewed histologically. The untreated patients (47 per cent) have been analysed for the incidence of malignant change and the patients with Class III lesions (carcinoma in situ) who were treated, were analysed for response to treatment. The mean follow-up period was 8.4 years. Only two of the 38 initially untreated patients of Class I (simple squamous cell hyperplasia) developed an invasive carcinoma. In Class II (hyperplasia with atypia), of 62 patients who were not treated initially, 17 developed a laryngeal squamous cell carcinoma later. Only six patients of Class III did not receive any treatment initially, and one of these progressed to invasive carcinoma. Almost all other patients with carcinoma in situ (Class III) were irradiated. In these patients no evidence of local recurrence was found.

Sign in / Sign up

Export Citation Format

Share Document